Europe approves Biocon's Rosuvastatin Calcium tablets
Bengaluru: Biotech major Biocon has received its first generic formulation approval in Europe, paving way for the company to launch Rosuvastatin Calcium tablets in several European countries.
Biocon has received European approvals for Rosuvastatin Calcium 5 mg, 10 mg, 20 mg and 40 mg tablets, a generic equivalent of Crestor tablets, indicated for hyperlipidemia or mixed dyslipidemia.
The approval in the regulated markets marks an important milestone in Biocon's small molecules strategy of forward integration from APIs.
Biocon has received European approvals for Rosuvastatin Calcium 5 mg, 10 mg, 20 mg and 40 mg tablets, a generic equivalent of Crestor tablets, indicated for hyperlipidemia or mixed dyslipidemia.
The approval in the regulated markets marks an important milestone in Biocon's small molecules strategy of forward integration from APIs.
Next Story
